Advances in pharmacotherapy for opioid-induced constipation - A systematic review

Expert Opinion on Pharmacotherapy

Volumn 16, Issue 4, 2015, Pages 515-532

  Siemens, Waldemar ^a   Gaertner, Jan ^a   Becker, Gerhild ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Constipation; Drug; Opioid; Pharmacotherapy; Review

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BEVENOPRAN; LUBIPROSTONE; NALOXEGOL; NALOXONE; NARCOTIC ANALGESIC AGENT; PRUCALOPRIDE;

ABDOMINAL PAIN; ADULT; CONSTIPATION; DEFECATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HEART DISEASE; HUMAN; NAUSEA; PAIN ASSESSMENT; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; PAIN;

ABDOMINAL PAIN; ANALGESICS, OPIOID; CONSTIPATION; DIARRHEA; GASTROINTESTINAL MOTILITY; HEADACHE; HUMANS; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84922952943     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2015.995625     Document Type: Review

References (64)

1. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72(14):1847-65
2. Poulsen JL, Brock C, Olesen AE, et al. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. CEG 2014;345-58
3. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009;373(9670):1198-206
4. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11S-8S
5. Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and european patient survey (PROBE 1). Pain Med 2009;10(1):35-42
6. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 2007;61(7):1181-7
7. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 2001;93(3):247-57
8. Coyne K, LoCasale R, Datto C, et al. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. CEOR 2014;23(6):269-81
9. Hjalte F, Berggren A, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40(5):696-703
10. Gaertner J, Siemens W, Camilleri M, et al. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol 2014;49(1):9-16
11. Joswick T, Mareya SM, Lichtlen P, et al. Time to onset of lubiprostone treatment effect in chronic non-cancer pain patients with opioid-induced constipation: data from two phase 3, randomized, doubleblind, placebo-controlled trials. Gastroenterology 2013;144(5 Suppl 1):540
12. Mareya SM, Lichtlen P, Woldegeorgis F, et al. Lubiprostone improves complete spontaneous bowel movement frequency in chronic non-cancer pain patients with opioid-induced constipation. Gastroenterology 2013;144(5 Suppl 1):539-40
13. Ishihara M, Iihara H, Okayasu S, et al. Pharmaceutical interventions facilitate premedication and prevent opioidinduced constipation and emesis in cancer patients. Support Care Cancer 2010;18(12):1531-8
14. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130(5):1377-90
15. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
16. Clemens KE, Quednau I, Klaschik E. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer. Int J Clin Pract 2011;65(4):472-8
17. Iyer SS, Randazzo BP, Tzanis EL, et al. Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms. Value Health 2011;14(1):177-83
18. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting muopioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebocontrolled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137(2):428-40
19. Wirz S, Nadstawek J, Elsen C, et al. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care 2012;21(1):131-40
20. Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):175-84
21. Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):185-93
22. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain 2009;13(7):737-43
23. Portenoy RK, Thomas J, Moehl BM, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35(5):458-68
24. Wirz S, Wartenberg HC, Nadstawek J. Less nausea, emesis, and constipation comparing hydromorphone and morphine?. A prospective open-labeled investigation on cancer pain. Support Care Cancer 2008;16(9):999-1009
25. Dorn S, Lembo A, Cremonini F. Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Am J Gastroenterol Suppl 2014;2(1):31-7
26. Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract 2014;2014(1):1-6
27. Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician 2008;11(2 Suppl):S105-20
28. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004;361(1-3):192-5
29. Mancini I, Bruera E. Constipation in advanced cancer patients. Support Care Cancer 1998;6(4):356-64
30. Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
31. Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 2014;370(25):2387-96
32. Webster L, Dhar S, EldonM, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154(9):1542-50
33. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23(1):48-53
34. Paulson DM, Kennedy DT, Donovick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioidinduced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 2005;6(3):184-92
35. Viscusi E, Barrett A, Paterson C, et al (451) Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis. J Pain 2014;15(4):S88
36. Michna E, Blonsky ER, Schulman S, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain 2011;12(5):554-62
37. Irving G, Penzes J, Ramjattan B, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):175-84
38. Jansen JP, Lorch D, Langan J, et al. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain 2011;12(2):185-93
39. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting muopioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebocontrolled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain 2008;137(2):428-40
40. Jamal MM, Mareya SM, Woldegeorgis F, et al. Lubiprostone significantly improves treatment response in non-methadone opioid-nduced bowel dysfunction patients with chronic, noncancer pain: results from a phase 3 randomized double-blind placebo-controlled clinical trial. Gastroenterology 2012;142(5):144-5
41. Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebocontrolled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, noncancer pain. Gastroenterology 2010;138(Suppl 1):S129
42. Loewenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10(4):531-43
43. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011(1):CD003448
44. Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral μ- opioid receptor antagonist methylnaltrexone. Drugs 2013;73(12):1297-306
45. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013;108(10):1566-74
46. Anissian L, Schwartz HW, Vincent K, et al. Subcutaneous methylnaltrexone for treatment of acute opioid-induced constipation: phase 2 study in rehabilitation after orthopedic surgery. J Hosp Med 2012;7(2):67-72
47. Rauck RL, Peppin J, Israel R, et al. Oral methylnaltrexone for the treatment of opioid-induced constipation in patients with noncancer pain. Gastroenterology 2012;142(Suppl 1):160
48. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009;7(1):39-46
49. Portenoy RK, Thomas J, Moehl BM, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage 2008;35(5):458-68
50. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008;358(22):2332-43
51. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13(1):56-64
52. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24(12):3503-12
53. Tack J, Corsetti M. Naloxegol for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 2014;8(8):855-61
54. Webster L, Chey WD, Tack J, et al. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Aliment Pharmacol Ther 2014;40(7):771-9
55. Cryer B, Katz S, Vallejo R, et al. A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Pain Med 2014;15(11):1825-34
56. Singla NK, Techner LM, Gabriel K, et al. CB-5945 0.25 mg Twice daily is associated with significantly increased spontaneous bowel movement and greater proportion of responders compared with placebo in patients on chronic opioid therapy for noncancer pain (45CL242; NCT01207427). Gastroenterology 2012;143(3):26-7
57. Lichtlen P, Joswick T, Woldegeorgis F, et al. Lubiprostone is well tolerated in chronic non-cancer pain patients with opioid-induced constipation in three phase 3, randomized, double-blind, placebo-controlled trials. Gastroenterology 2013;144(5 Suppl 1):916
58. Mackey AC, Green L, Greene P, et al. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40(1):e1
59. Bader S, Dü rk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol 2013;7(1):13-26
60. Entereg (Alvimopan) Capsules. Safety labeling changes approved by FDA center for drug evaluation and research (CDER). U.S FDA. 2013. Available from: http://www.fda. gov/safety/medwatch/safetyinformation/ucm194328.htm [Last accessed 3 November 2014
61. Levels of evidence. Oxford centre for evidence-based medicine 2009. Available from: http://www.cebm.net/oxfordcentre- evidence-based-medicine-levelsevidence- march-2009/[Last accessed 28 October 2014
62. Higgins JPT, Altman DG. editors. Assessing risk of bias in included studies. John Wiley & Sons; Sussex: 2008
63. Meerpohl JJ, Langer G, Perleth M, et al. GRADE-Leitlinien: 3. Bewertung Der qualität Der evidenz (vertrauen in die effektschätzer). zeitschrift für evidenz, fortbildung und qualität im gesundheitswesen. 2012;106(6):449-56
64. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62(10):1006-12